(Total Views: 327)
Posted On: 06/01/2018 12:17:27 PM
Post# of 72446
If partnerships, I see good upfront cash and great backend royalties.
If cash for whole company now, it would have to be gigantic or Leo will hold out for products to flesh out (how large will P be in dermatology and autoimmune indications, how massive will B prove to be in indications not even being researched yet as it seems to cross many, many boundaries of various medical needs, how complementary a compound will K prove to be for many cancer treatments).
End result is MASSIVE. How we get there we will find out once P results are given and Leo can give some indication of the pathway he (and Drs. B and M) believe will maximize IPIX value.
I believe most numbers I hear thrown around today could prove quite low compared to what the final end value of the company turns out to be. I dare to say that what IPIX has in its pipeline today could be the largest collective trove of new products ever to have been offered by a biotech startup and I believe Leo knows that.
If cash for whole company now, it would have to be gigantic or Leo will hold out for products to flesh out (how large will P be in dermatology and autoimmune indications, how massive will B prove to be in indications not even being researched yet as it seems to cross many, many boundaries of various medical needs, how complementary a compound will K prove to be for many cancer treatments).
End result is MASSIVE. How we get there we will find out once P results are given and Leo can give some indication of the pathway he (and Drs. B and M) believe will maximize IPIX value.
I believe most numbers I hear thrown around today could prove quite low compared to what the final end value of the company turns out to be. I dare to say that what IPIX has in its pipeline today could be the largest collective trove of new products ever to have been offered by a biotech startup and I believe Leo knows that.
(8)
(0)
